Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who’s Hired? Pfenex’ Lucy Joins Lykan Bioscience

As Samsung Biologics Names New President And CEO

Executive Summary

Pfenex founder and chief business officer Patrick Lucy has left the company to join Lykan Bioscience. Meanwhile, Samsung Biologics has announced the appointment of a new president and CEO, as the Australian generics and biosimilars association appoints a new chair.

You may also be interested in...



Adcock Struggles As South African Healthcare Awaits Relief

Despite a slight increase in revenue, South Africa’s Adcock continues to struggle as it reports a continued drop in gross profit. The company expects the economy to remained constrained due to COVID-19, but is eagerly anticipating recovery with the government’s vaccine roll-out.

Australia Welcomes Advent Of INN Prescribing

Prescribing reforms introduced from the start of February in Australia will see doctors prioritize active ingredients over brand names, following negotiations with government by the country’s GBMA off-patent industry association.

GBMA Set For New Australian Pact

Australian off-patent industry association the GBMA says it has begun negotiations on a new strategic agreement with the government that will offer “long-term certainty” for the sector. Meanwhile, the industry body has praised the latest “pandemic budget” measures to address the impact of COVID-19.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB150555

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel